Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. (Q43696432)
Jump to navigation
Jump to search
scientific article published in February 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. |
scientific article published in February 2002 |
Statements
1 reference
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. (English)
1 reference
Christina Voelkel-Johnson
1 reference
Deanne Lea King
1 reference
James Scott Norris
1 reference
1 February 2002
1 reference
1 reference
9
1 reference
2
1 reference
164-172
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference